Timothy M Mayleben insider trades: Esperion Therapeutics (ESPR) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Timothy reports to the SEC
and 1 more company
Open-market buys and sales
24 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 11, 2020 | ESPR | ↑ Buy | 2,500 | $43.00 | $108K | Direct | Mar 12, 2020 (1d) |
| Feb 28, 2020 | ESPR | ↑ Buy | 5,000 | $49.00 | $245K | Direct | Mar 2, 2020 (3d) |
| Nov 6, 2019 | ESPR | ↑ Buy | 5,000 | $36.98 | $185K | Direct | Nov 8, 2019 (2d) |
| Sep 6, 2019 | ESPR | ↑ Buy | 7,500 | $34.55 | $259K | Direct | Sep 6, 2019 (0d) |
| Aug 1, 2019 | ESPR | ↑ Buy | 5,000 | $39.56 | $198K | Direct | Aug 2, 2019 (1d) |
| Jun 28, 2019 | ESPR | ↑ Buy | 5,000 | $46.00 | $230K | Direct | Jul 1, 2019 (3d) |
| Mar 29, 2019 | ESPR | ↑ Buy | 5,000 | $40.00 | $200K | Direct | Apr 1, 2019 (3d) |
| Mar 20, 2019 | ESPR | ↑ Buy | 5,000 | $43.48 | $217K | Direct | Mar 21, 2019 (1d) |
| Mar 14, 2019 | ESPR | ↑ Buy | 5,000 | $48.73 | $244K | Direct | Mar 14, 2019 (0d) |
| Jun 8, 2018 | LOXO | ↓ Sell | 10,000 | $179.55 | $1.8M | Direct | Jun 11, 2018 (3d) |
| Dec 20, 2017 | LOXO | ↓ Sell | 10,000 | $80.49 | $805K | Direct | Dec 22, 2017 (2d) |
| Nov 22, 2017 | LOXO | ↓ Sell | 3,000 | $75.85 | $228K | Direct | Nov 27, 2017 (5d) |
| May 4, 2016 | ESPR | ↑ Buy | 7,000 | $14.85 | $104K | Direct | May 5, 2016 (1d) |
| Jan 27, 2016 | ESPR | ↑ Buy | 3,600 | $15.88 | $57K | Direct | Jan 28, 2016 (1d) |
| Jan 15, 2016 | ESPR | ↑ Buy | 7,200 | $14.08 | $101K | Direct | Jan 19, 2016 (4d) |
| Jul 1, 2013 | ESPR | ↑ Buy | 5,000 | $14.00 | $70K | Direct | Jul 1, 2013 (0d) |
| Aug 8, 2011 | ASTM | ↑ Buy | 10,000 | $2.11 | $21K | Direct | Aug 9, 2011 (1d) |
| Aug 5, 2011 | ASTM | ↑ Buy | 20,000 | $2.36 | $47K | Direct | Aug 8, 2011 (3d) |
| Mar 3, 2011 | ASTM | ↑ Buy | 21,382 | $2.12 | $45K | Direct | Mar 4, 2011 (1d) |
| Nov 24, 2010 | ASTM | ↑ Buy | 12,000 | $2.19 | $26K | Direct | Nov 29, 2010 (5d) |
| Aug 30, 2010 | ASTM | ↑ Buy | 17,200 | $1.45 | $25K | Direct | Aug 31, 2010 (1d) |
| May 21, 2010 | ASTM | ↑ Buy | 17,600 | $1.42 | $25K | Direct | May 25, 2010 (4d) |
| Mar 8, 2010 | ASTM | ↑ Buy | 33,956 | $1.46 | $50K | Direct | Mar 9, 2010 (1d) |
| Aug 16, 2006 | NHWK | ↑ Buy | 4,000 | $16.29 | $65K | Direct | Aug 17, 2006 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ESPR insiders
Open-market trades in the last 12 months
About Timothy M Mayleben's insider trades
Timothy M Mayleben is President & CEO at Esperion Therapeutics (ESPR). Since Aug 16, 2006, Timothy has reported 21 open-market purchases worth $2.5M and 3 sales worth $2.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (48 filings), shares returned to the company (5 filings), option exercises (5 filings), gifts (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ESPR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.